Administration Intravesical Drug Therapy/instrumentation Humans Neoplasm Invasiveness Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/pathology Emda Nmibc NMIBC Carcinome de la vessie TURBT EMDA RITE Synergo Rite Synergo Turbt Urothelial carcinoma

Bladder cancer blood transfusion cystectomy oncology prognostic marker urothelial carcinoma

diagnosis meta-analysis urinary bladder urine biomarkers urothelial carcinoma BioScience Corp. Norihiko Masuda Osamu Ogawa Meyeon Park Alvin Y Liu Yunfeng Dai Landon Kozai Hideki Furuya Yair Lotan and Takashi Kobayashi declare that they have no conflicts of interest.

Carcinoma Papillary/mortality/pathology/*therapy Disease Progression Humans Neoplasm Staging Progression-Free Survival Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/mortality/pathology/*therapy Urothelium/*pathology Bacillus Calmette-Guérin therapy Bladder cancer Bladder sparing Immediate cystectomy Micropapillary Prognosis Transurethral resection Urothelial carcinoma Variant histology

B7-H1 Antigen/*metabolism Biomarkers Tumor/metabolism Carcinoma Transitional Cell/metabolism/*mortality/pathology Cell Membrane/metabolism Gene Expression Regulation Neoplastic Humans Neoplasm Staging Prognosis Survival Analysis *Up-Regulation Urinary Bladder Neoplasms/metabolism/*mortality/pathology Biomarker Meta-analysis Pd-l1 Urothelial carcinoma

Databases Factual Disease-Free Survival Humans Lymphocytes/*cytology/immunology Neoplasm Metastasis Neutrophils/*cytology/immunology Odds Ratio Prognosis Proportional Hazards Models Risk Assessment Survival Rate Urinary Bladder Neoplasms/immunology/mortality/*pathology Urologic Neoplasms/immunology/mortality/*pathology Bladder cancer Metastatic unresectable urothelial carcinoma Neutrophil-Lymphocyte ratio Unresectable urothelial carcinoma

Female Humans Male Prospective Studies Sex Factors Urinary Bladder Neoplasms/*etiology Urinary Tract Infections/*complications Bladder cancer Cystitis Urinary bladder neoplasms Urinary tract infections Urothelial carcinoma

Ki-67 bladder cancer meta-analysis prognosis urothelial carcinoma

Biomarkers Tumor/*urine Carcinoma Transitional Cell/pathology/*urine Gene Expression Regulation Neoplastic Humans Prognosis RNA Long Noncoding/*urine Urinary Bladder Neoplasms/pathology/*urine Bladder cancer biomarker diagnosis long non-coding RNA urothelial carcinoma–associated 1

Carcinoma Transitional Cell/pathology/*surgery Cystectomy/*methods Humans Kaplan-Meier Estimate Neoplasm Recurrence Local Risk Factors Urethra/*pathology Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/pathology/*surgery Bladder cancer Neobladder Radical cystectomy Urethral recurrence Urothelial carcinoma

Humans *Hyperthermia Induced Treatment Outcome Urinary Bladder Neoplasms/*therapy Bladder cancer chemohyperthermia radiohyperthermia regional hyperthermia therapy urothelial carcinoma

*Health Status Humans *Life Style *Quality of Life Survivors/*psychology Urinary Bladder Neoplasms/*psychology/therapy Bladder cancer Diet Exercise Lifestyle factors Quality of life Smoking Urothelial carcinoma

Kaplan-Meier Estimate Neoplasm Grading Neoplasm Metastasis Neoplasm Staging Odds Ratio Prognosis Publication Bias Urinary Bladder Neoplasms/*mortality/*pathology/therapy histological variants squamous differentiation urothelial carcinoma of the bladder including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Biomarkers Tumor/genetics DNA Methylation Epigenesis Genetic *Gene Expression Regulation Neoplastic Humans Prognosis Retrospective Studies Urinary Bladder Neoplasms/*genetics Chromatin remodeling Methylation Non-coding RNA Progression Recurrence Urothelial carcinoma